CHAIRMAN’S LETTER

Dear Friends and Colleagues,

The academic mission of the Havener Eye Institute for 2006 – 2007 has been advanced by the significant research progress made in the areas of ocular biomechanics, ocular melanoma, and pseudotumor cerebri through translational endeavors between our basic scientists and physicians. We are also involved in multiple clinical trials encompassing all areas of ophthalmology.

The Department of Ophthalmology is committed to training the next generation of ophthalmologists and physician leaders. This year is our first year with a full fifteen resident contingent after increasing our residency size two years ago. The quality and quantity of resident applicants is at an all time high. Resident surgical volumes have increased dramatically. Our graduating residents continue to represent our department in stellar fashion through outstanding performance on their board examinations and in fellowship and in practice. The fellowship programs have continued to expand with one fellow each in Cornea, Glaucoma, Retina, and Neuro-Ophthalmology/Oculoplastics. Our clinical fellows have contributed significantly to each of the three missions of the department; education, research, patient care.

The faculty, staff, and residents are proud of providing state of the art ophthalmic care to the citizens of Ohio and beyond. Last year we had 52,216 outpatient visits and 3429 surgeries at the Havener Eye Institute, Columbus Children’s Hospital Eye Clinic, Columbus Veterans Administration Outpatient Clinic, and the Dayton Veterans Administration Hospital. The volume, scope, and complexity of our patient care activities continues to grow.

I want to thank our many friends, colleagues, and alumni who have supported the department in many ways through the years to establish a tradition in ophthalmology. In the context of this rapid progress, we are committed to identifying a larger facility to consolidate our clinical, research, and educational activities. We welcome your involvement with our vision of growth for the Havener Eye Institute.

I hope you enjoy our annual report.

Sincerely,

Thomas F. Mauger, M.D.
Director and Chairman, Havener Eye Institute
OSU Department of Ophthalmology
The Carl & Grace Baldwin Chair
About the Havener Eye Institute

The William H. Havener Eye Institute, Department of Ophthalmology, at The Ohio State University prides itself in providing state-of-the-art patient care, education and research. The Institute is a center within the nationally recognized Ohio State University Medical Center, a 900 bed tertiary care center with three operating rooms dedicated to ophthalmology. Our department offers patients the latest examination and diagnostic techniques, and medical and surgical treatments. Services range from routine eye examinations and contact lens fitting to the most up-to-date laser and surgical treatments for such major diseases as glaucoma, diabetic eye disease, corneal disorders, macular degeneration, and cataracts, as well as the latest techniques in refractive surgery. The department sees over 50,000 patients a year, or nearly one quarter of the entire outpatient visits of The Ohio State University Hospitals Clinic.

The department’s three-year residency program is one of the most competitive in the country. Our fellowship training offers numerous clinical, surgical, research and teaching opportunities in the areas of cornea and external disease, refractive surgery, vitreoretinal disease and surgery, neuro-ophthalmology/orbital disease and surgery, and glaucoma management and surgery. Our faculty are involved in a number of multi-center clinical trials funded by the National Eye Institute, and have published major textbooks recognized for advancing ophthalmic medical education.

Through their research, our faculty members contribute to medicine’s base of knowledge of ocular diseases through efforts aimed at new treatments for the prevention and treatment of blinding disorders. Our involvement in multiple research programs funded by the National Eye Institute/National Institutes of Health is helping to develop standards of care for many of the major causes of blindness. Our faculty and staff members’ participation in numerous professional and service organizations continues to enhance the profession and provide leadership in the field. The William H. Havener Eye Institute is working everyday...

Establishing A Tradition in Ophthalmology
Havener Society

The Havener Society was established in the late 1980s by the students of William Havener to perpetuate the principles and high standards that he set for himself and for the students and benefactors of his talents. Qualifying donations for both the Havener Society and the Annual Honor Roll are those that support the educational and research mission of the department. This includes funds donated for resident and fellow salary support, equipment used by residents and students in clinic, student and resident educational programming, books for the department library, named lectureships, and support of chairs and faculty positions.

William H. Havener, MD was the first full-time ophthalmologist at The Ohio State University College of Medicine and Public Health and chairman of the Department of Ophthalmology from 1959-1961 and 1972-1988. A distinguished teacher and internationally known author, Dr. Havener was an innovative and skillful surgeon, thoughtful citizen, an avid gardener, and most of all, a considerate and caring physician. Dr. Havener believed in planting things and watching them grow. He loved to plant seeds, whether in his garden or by nurturing medical students, residents, and faculty.

For four decades, he had a single mission: Ophthalmology. With his keen powers of observation and unique ability to transmit knowledge to others, as an educator, he had no peer. He was directly responsible for the training of over 200 ophthalmologists and thousands of medical students. The great planter of seeds is gone, but his harvest will continue to be bountiful.
Establishing a tradition in Ophthalmology

Havener Circle
$1,000,000 and above
Carl M Baldwin*
Grace C Baldwin*
Warner & Patti Blow
Irene D Hirsch*

Chairman Circle
$500,000 – $999,999
Martha Staub*

Faculty Circle
$100,000 – $499,999
Phyllis Havener
Dr. William H. Havener*
Dr. Milton C. Oakes*

Fellow Circle
$50,000 – $99,999
Dr. Douglas Baker
Dr. John Burns
Dr. Kenneth Cahill
Jerry R. Colp
Dr. Henry & Suzanne Croci
Dr. Frederick Davidorf
Leo & Grace Faust*
Margery Henderson*
Dr. Roger C Henderson*
Gayle Huffman*
Eleanor Kilgore*
Dr. Richard H Keates
Mary K Laughlin*
Dr. Alan Letson
Dr. Holton Letson
Dr. Torrence Makley*
Dr. Thomas Mauger &
Dr. Carol Laxson
Ruby Nowak*
Ruth Tankersley*
Eldon J Tobias*

*Indicates Deceased

Resident Circle
$25,000 - $49,999
Dr. Robert Chambers
Helen Clabaugh*
Helen Coast*
Helen Crane*
Dr. Jack & Candace Hendershot
Dr. Marilyn J. Huheey
Katherine Kessler*
Dr. Robert Magnuson*
Dr. Robert & Helen McKinlay
Lois Ann Moor
Dr. Alfred Nicely
Dr. Dick Nisbet
Dr. Karl Pappa
Dr. John Stechschulte
Dr. Dale & Bonnie Solze
Elmer Tankersley*
Dr. Paul Weber

Student Circle
$10,000 – $24,999
Dr. David Adam
Dr. Donald Anderson
Dr. James Andrew*
Dr. Paul Armstrong
Dr. William Banks III
Dr. Morris Battles*
Dr. Susan Benes
Dr. James Bennett*
Joseph L Bitonte*
Dr. Wilbur Blount*
Dr. Hans Bredemeyer
Dr. Robert Bruce*
Dr. Robert Bruce, Jr.
Howard Burnett
Dr. Patrick Carroll
Dr. Elson Craig
Dr. Robert Derick
Dr. Jack Dingle
Gladys Dunlap*
Gilbert Eggleston

Harry Esbenshade, Jr.
Dr. Sanders Farber
Dr. John Charles Garvin
Edward Gerhold, Sr.*
Dr. Gregory Gibb
Florence Johnson*
Dr. Fred & Audrey Kapetansky
Dr. John D. Kay
Dr. Curtin Kelley
Dr. Charles Kunesh*
Dr. Richard Lembach
Dr. Jerrold Levin
Dr. Donald Lewis
Dr. John Mader
John L Marakas
Dr. W. Thomas Martin
Dr. Randy McLaughlin
Timothy McNemar
Ann E. Meiling*
Dr. Carl Minning, Jr.
Dr. James Moses
Marlene O’Dair
Dr. Robert O’Dair*
Dr. E. Mitchel Opremcak
Dr. Richard Orlando
Dorothy Osborne
Maude Osborne*
Dr. Paul Richards
Mrs. Ermal Roberts
Mary Ellen Sharshal
Dr. Carl Shin
Dr. Richard Simmons
Dr. James Stewart
Dr. Ted Suie, Jr.*
Dr. Lloyd Taustine
Patti Tewell
Dr. Peter Utrata
Dr. Albert Van Fossen
Dr. Joel Wachtel*
Dr. Charles Zepp
Harold F Zieg*
2007 Annual Honor Roll

In conjunction with the Havener Society, our Annual Honor Roll tracks yearly philanthropic donations to the department. After an individual’s yearly contributions have accumulated to $10,000, members of the Annual Honor Roll will be listed in the Havener Society lifetime recognition program.

$100,000 and above
Warner & Patti Blow

$50,000 to $99,999
Dr. Henry & Suzanne Croci
Dr. Holton C. Letson

$10,000 to $49,999
Jerry Colp
Harry Esbenshade

$5,000 to $9,999
Dr. Jack & Candace Hendershot
Dr. D.M. Nisbet
Dr. Dale & Bonnie Solze

$2,500 to $4,999
Dr. Dave & Cheryl Adam
Dr. Patrick Carroll
Dr. Alan & Susan Letson
Dr. Robert McKinlay
Dr. Garrett Mouser
Dr. Jeff & Dr. Mary Oehler
Dr. Karl & Michelle Pappa

$1,000 to $2,499
Mary & Howard Burnett
Dr. Ivan & Marcie Gilbert
Carolyn Greshemer
Phyllis Havener
Dr. Thomas Mauger
Dr. Carl & Joan Minning
John Marakas
Dr. James Moses
Dr. Baird Pfahl
Dr. Carl Shin
Dr. John J. Wilding

$500 to $999
Dr. Howard & Pamela Bell
Robert Hamm
Dr. Lawrence Kams
Dr. L.Carol Laxson
Dr. Charles Leone Jr.
Dr. Larry Lohman
Bernard & Doris Mudrock
Richard Poffenbaugh
Paul Ritter Jr.
Dr. David Stager
Dr. C. Michael & Sandra Thorne
David Ullman

$100 to $499
Alan Alford
Dr. Doug Baker
Scott Bellinger
Thomas Baxter
Judy Burke
Dr. John Burns
Dr. John Christoforidis
Albert Covelli
Dr. Jonathan Davidorf
Dr. Jack Dingle
Margery K. Forry
Justa Garrett
Tally M. Grossman
Steve Grub
Hilde Hartline
Benjamin Haynes
Audrey Henry
Irma Huber
Thomas Jenkins
Ben & Anne Kauffman
Dr. Ali Keyhani
Dr. James King

$100 to $499 (Cont)
Bob Lafollette
Barbara Landolfi
Dr. Max J. Lerner
Bill Martin
Dr. Jeff & Sue McAdoo
Kathy McKinney
Dr. Randy McLaughlin
Tim McNemar
Martha Morris
Frank New
Dr. Alfred Nicely
Fred & Cheryl Nicely
Dr. Phillip O’Donnell
Pam Potter
Floyd & Patricia Redd
Lee Rudibaugh
Michael Sauer
Charles Sauers
T. Dwain Sayre
Nasser Sharifrazi
Dr. Jerry Shell
B. Lee Skilken
Laura Sladoje
Dr. John Stechshulte
Michael Steyer
Dr. Michael Stone
Dr. Paul Treger
Dr. Paul Weber
Lisa Williamson
Dr. Jeffrey Wincko
Establishing a tradition in Ophthalmology

One Million Dollar Gift
Patti and Warner Blow Advancing Research

Since 2001, Patti and Warner Blow of Naples, Florida, have been generously giving back to their adopted Columbus community by supporting vision research at the William Havener Eye Institute at The Ohio State University. They have established the Patti Blow Research Fund to advance research in angiogenic diseases of the eye. Both are patients of the Havener Eye Institute. “We have had the privilege of working with Dr. Frederick Davidorf and the Department of Ophthalmology for several years. It is most gratifying to witness a group of dedicated professionals start with some basic ideas and evolve to an ever-maturing research organization,” says Warner Blow. According to the Blows, the goal of their contributions is to support basic research with an emphasis on diseases such as diabetic retinopathy, age-related macular degeneration, and melanoma of the eye.

“We strongly believe that grassroots efforts will be the source of major breakthroughs in the continuing fight against the frailties of the human body,” he added.

Faust Donation
Research Endowment

According to one of her best friends, Grace Faust derived her greatest pleasure and happiness from achieving for Ohio State. “Whatever she set out to do she got done,” assured Nancy Faulker. “Grace Heck Faust was an Ohio State alumna of the first order.”
Grace earned a bachelor’s degree from Ohio State in 1928, followed by a law degree in 1930. She was the university’s first female law school graduate. Leo Faust was also a Buckeye, receiving a law degree in 1926. She and Leo knew each other professionally during the 1930’s when she served as Ohio’s first female prosecutor and he an attorney. According to the Faulkers, Grace never considered herself a feminist or a crusader, but rather a woman who considered her own personal path and interests and met all colleagues on an equal footing. After a lifetime of pioneering - first a career in law then serving as a judge in Urbana–and sharing her devotion to Ohio State, Grace received a distinguished Alumni Award from the university. In her 80’s at the time, Grace leaned over to her friend Nancy before taking the stage and said in her characteristic style, “It’s about damn time.” Leo continued to go to the office every day, even well past 92 years of age. Grace passed away in 1994, followed by Leo in 1996. The Fausts contributed to Ophthalmology in honor of Faulkers’ late son, J. Andrew Faulker, who was also a partner in the law firm. Andy suffered from a retinal disease. Their endowed fund is used for research into the causes, preventions and cures of retinal diseases.
Moor Endowment

For Lois Ann Moor and her family, the decision to create an endowment in ophthalmology honoring her late husband was a natural connection based on gratitude.

“The idea for the fund was to contribute to ophthalmology because Dr. Havener saved Ted’s sight, which enabled him to continue his teaching career in dentistry at Ohio State for 17 years,” she recalled. Theodore Lyman Moor, (D.D.S. 1951), served on the Ohio State College of Dentistry faculty from 1971 to 1988. It was through the care of the late Dr. William Havener that Dr. Moor was able to have his sight restored and sustained, according to Mrs. Moor.

To the Moor family, this gift of vision was a significant milestone and in 2005 they established the Dr. Theodore Lyman Moor Graduate Student Research Fund. The endowment supports research activities and the dissemination of research findings of a graduate student engaged in ophthalmic research in the Department of Ophthalmology.

As lifelong Columbus residents who raised three children, Lois and Ted Moor always appreciated their connections to OSU. Mrs. Moor obtained a B.S. degree in Business Administration in 1952 and met her late husband shortly after he graduated from Ohio State. She was a member of the Alumni Scholarship House and later served on its board. For 23 years she was a teacher in the Columbus Public Schools.

“I could not have graduated college without the Scholarship House,” she noted, “and Ted and I were both very grateful to Ohio State. It paved the way for our lives and our educational paths.” Her husband’s appreciation for medical research and teaching can now be carried on through the endowment, according to Mrs. Moor. By supporting promising research to improve the diagnosis and treatment of vision diseases, many more patients and their families will be given a second chance, she said.

“We truly appreciate the foresight and partnership of the Moor family in creating this important fund,” said Dr. Thomas Mauger. “Supporting the best young researchers and graduate students who are interested in eye diseases will advance care for all of our patients.”

Nicely Endowment

The Alfred L. Nicely M.D. Resident Education Fund in Ophthalmology has been created with a $25,000 gift from Akron resident Alfred L. Nicely M.D., who received both his bachelors and medical degrees from Ohio State. The Ohio State University Board of Trustees formally approved the endowment at the September 2006 board meeting.

Dr. Nicely, who is currently retired, received his bachelor’s degree in Biological Sciences in 1957 and his Medical Degree in 1961. He served his residency in ophthalmology at Ohio State from 1962 – 1965. He then practiced general ophthalmology in the Akron area for several decades.

Funds from the Nicely endowment will be used to support the education and training of the 15 full-time medical residents in the Department of Ophthalmology during their three-year residency training at Ohio State. Dr. Nicely and his wife, retired Judge Judith Bowers Nicely, have two sons who reside in Columbus.

“This gift from Dr. Nicely is a wonderful example of the significant impact our faculty and physicians have had over many years in training our residents,” said Dr. Thomas Mauger, chair of the department. “We are grateful to Dr. Nicely for his generosity in creating a new resource to enhance and strengthen our residency training program. Private support truly advances our mission in teaching and patient care.”
FACULTY
Establishing a tradition in Ophthalmology

New Faculty

Professor Emeritus
Richard Keates, M.D.

Clinical Professors
Susan C. Benes, M.D.
John A. Burns, M.D.
Kenneth V. Cahill, M.D.
Frederick Kapetansky, M.D.
Gary L. Rogers, M.D.

Clinical Associate Professors
Hans Bredemeyer, M.D.
Don L. Bremer, M.D.
Robert A. Bruce, M.D.
Robert Chambers, D.O.
Robert J. Derick, M.D.
Jack Dingle, M.D.
John W. Higbee, M.D.
Curtin G. Kelley, M.D.
Lawrence E. Leguire, Ph.D.
Robert E. Lembach, M.D.
Martin Lubow, M.D. (Emeritus)
Robert T. McKinlay, M.D.
E. Mitchel Opremcak, M.D.
Roger H. Sherman, M.D.
Richard E. Simmons, M.D.
George Stine, M.D.
Peter J. Utrata, M.D.

Clinical Assistant Professors
David R. Adam, M.D.
Charlotte M. Agnone, M.D.
J. Geoffrey Allen, M.D.
N. Douglas Baker, M.D.
Kenneth Beckman, M.D.

Establishing a tradition in Ophthalmology

New Faculty

Reynell Harder Smith, D.O.
Assistant Professor
Anterior Segment

Amy Kopp, M.D.
Assistant Professor
Glaucoma

John Christoforidis M.D.
Assistant Professor
Retina

Amit Tandon, M.D.
Assistant Professor
Comprehensive

Robert P. Bennett, M.D.
Michael Bessot, M.D.
Kenneth A. Boyle, Jr., M.D.
Bruce Buerk, M.D.
C. Patrick Carroll, M.D.
Cybil Bean Cassady, M.D.
George M. Chioran, M.D.
Louis Chorich III, M.D.
Elmer C. Collins, M.D.
Elliott Davidoff, M.D.
David E. Denlinger, M.D.
Alice T. Epitropoulos, M.D.
Avrom D. Epstein, M.D.
Kelly Everman, M.D.
Sanders M. Farber, M.D.
Jill A. Foster, M.D.
J. Charles Garvin, M.D.
Walter C. Hartel, M.D.
Farreed Hasan, M.D.
James McHale, M.D.
Charles J. Hickey, M.D.
Marilyn J. Huheey, M.D.
Marsha Kavanagh, M.D.
Kevin G. Kegler, M.D.
Steven M. Kirkham M.D.
Dino Klisovic, M.D.
Heather C. Koelling, M.D.
Susmitha P. Koll, M.D.
Marilyn K. Kosier, M.D.
John Kunesh, M.D.
Michael T. Kunesh, M.D.
Mark S. Law, M.D.
David M. Lehmann, M.D.
Charles Letson, M.D.
Richard Liston, M.D.
Mark Lomeo, M.D.
John L. Marquardt, M.D.
A. Marie Martinek, M.D.
Mary Lou McGregor, M.D.
Carl A. Minning Jr., M.D.
Jennifer A. Morrison, M.D.
James L. Moses, M.D.
Paul Moyer, M.D.
Jeffrey C. Oehler, M.D.
Richard G. Orlando, M.D.
John T. Paikka, M.D.
Karl S. Pappa, M.D.
Sugat Patel, M.D.
Abhik Ray-Chaudhury, M.D.
Alan J. Rehmor, M.D.
Chester D. Ridenour, D.O.
David Rogers, M.D.
Nicholas Rogers, M.D.
Stephen C. Schumann, M.D.
Shahin Shahinfar, M.D.
James E. Silone, D.O.
Warren M. Sobol, M.D.
Brian R. Stahl, M.D.
John R. Stechschulte, M.D.
Steven H. Suh, M.D.
Annette Terebuh, M.D.
Phyllis Visocan, M.D.
Todd E. Whitaker, M.D.

Research Scientists
Jennifer Lewis, Ph.D.
Jun Liu, Ph.D.
Havener Eye Institute
2007 Annual Report

Residency Program
Residency Director
Alan Letson, M.D.
Program Coordinator
Trish Rebish

Grand Rounds
10 Specialty Grand Rounds
24 Case Presentation Grand Rounds
1 International Ophthalmology

Annual Ophthalmology Research Symposium
June 15, 2007

Ophthalmology Award Recipients:
Residents:
First Place: Matthew Ohr, M.D.
Second Place: Garret Mouser, M.D.
Third Place: Carrie Lembach, D.O.
Andrea Knellinger, M.D.

Graduate Students:
First Place: David W. Holman, B.S.
Second Place: Huikai Karol B.S.
Third Place: Shelley M. Glimcher, B.S.

Makley-Battles Teaching Award* Recipients:
Alan Letson, M.D.
Robert Chambers, D.O.

*The Makley-Battles Teaching Award is given annually in recognition of outstanding faculty contributions to resident education

Fellows
Marc R. Criden, M.D.
Ryan Deasy, M.D.
Reynell Harder Smith, D.O.
Amy Kopp, M.D.

Third Year Residents
Jeffrey T. Wincko, M.D. J. Jefferds Sinclair, M.D.
Carrie A. Lembach, D.O. J. Garret Mouser, M.D.

Second Year Residents
Matthew P. Ohr, M.D. Julie Lange, M.D.
Kathryn R. Baker, M.D. Thomas J. Dingle, M.D.
Anne Elbiaadi, M.D.

First Year Residents
Andrea Knellinger, M.D. Carla Ford, M.D.
Ted Loizos, M.D. Anupama Horne, M.D.
Andy Hendershot, M.D.
DIVISION REPORTS
Anterior Segment

Thomas F. Mauger, M.D.

The Anterior Segment Division continues with its mission of service, clinical care, research, and education. The faculty in the cornea division currently includes Richard Lembach, M.D., Richard Keates, M.D., Matthew Dangel, M.D., Thomas Mauger, M.D., David Castellano, M.D., and Amit Tandon, M.D. The division has an ongoing fellowship program and our cornea fellow, Reynell Harder Smith, D.O. completed training in June 2007. She remained with the division as a new faculty member.

The division is currently involved in a number of clinical and basic research projects. Clinical trials include evaluation of fungal and acanthameoba keratitis, lens capsule staining techniques, and intra-operative topography. The division research projects are also involved with Dr. Cynthia Roberts’ laboratory. Investigations of the biomechanical properties of the eye in health and disease utilizing new technologies are performed in this laboratory and in the clinical setting.

At the 2007 ARVO meeting, our division was well represented with thirteen abstracts. We had thirteen peer-reviewed publications during that time. The division is actively performing newer forms of corneal transplantation such as endothelial keratoplasty (DSAEK) and corneal stem cell transplantation. We are integrating the Intralase femtosecond laser with both the refractive and corneal aspects of the division.

During the year, resident and medical student teaching was accomplished with staffing clinics and surgeries at The Ohio State University Medical Center, Children's Hospital and Columbus Veterans Administration Outpatient Clinic as well as didactic lectures at OSU.

Central Ohio Lions Eye Bank

As a result of a landmark Lions fund-raising campaign for equipment, the Central Ohio Lions Eye Bank was among the first in the nation to commence the service of pre-cutting corneas for Descement’s Stripping Automated Endothelial Keratoplasty (DSAEK) during 2006-07. This program has been highly successful and as a result the Eye Bank has experienced increased surgeon utilization. Over 25% of the transplants now performed in the Eye Bank’s service area utilize this technique.

The Eye Bank received an $81,000 grant this year from Ohio’s Second Chance Trust Fund to create an on-line continuing professional education opportunity for health care and hospital staff responsible for discussing eye donation with families of deceased patients. Allergan was among the top contributors to the Eye Bank’s development efforts in 2006-07.

Dr. Richard Lembach is the Surgeon Director of the Central Ohio Lions Eye Bank and Dr. Thomas Mauger serves on the Board of Trustees.
Glaucoma
Paul A. Weber, M.D.

The glaucoma division continues in its endeavors of improving the diagnosis and treatment of glaucoma through research, educational efforts and providing exceptional clinical care.

In the realm of research, this year saw the conclusion of the four-year industry supported study exploring the new area of glaucoma management, neuroprotection. The clinical trial sponsored by Allergan was to evaluate the safety and effectiveness of oral Memantine, part of a class of drugs referred to as neuroprotectors. As of September 2006, all patients concluded their participation in this study. Now, the final process of data analysis will begin with results expected to be published in two years. Hopefully, findings will be favorable and Memantine can be added to the arsenal of medications that fight the progression of glaucoma.

The past year marked the 13th year of our participation in the Ocular Hypertension Treatment Study (OHTS). Findings from this NIH-NEI funded study have already resulted in dramatic shifts in managing ocular hypertension and glaucoma. This study has expanded to look at genetics, quality of life and the impact of glaucoma on individuals’ lives. Though the OHTS project will be concluding in 2008, the results have been extremely important and have already changed the way the way we treat patients with ocular hypertension and glaucoma.

This division’s faculty, consisting of Dr. Paul Weber, Dr. Gloria Fleming, Dr. Annette Terebuh and Dr. Amy Kopp will continue to contribute their expertise to ensure the highest standard of care to their patients in fighting the blinding disease of glaucoma.

Neuro-Ophthalmology
Steven Katz, M.D.

The Neuro-ophthalmology division continues to contribute to the departmental mission in the core areas of clinical care, teaching and research. Departmental faculty including David Hirsch MD, Susan Benes MD and Steven Katz MD are responsible for the Resident lecture series as well as medical student teaching in neuro-ophthalmology.

The Neuro-ophthalmology Research Group has been recognized nationally for research in the area of idiopathic intracranial hypertension (IIH). Our first papers describing a model of cerebrospinal egress through the arachnoid granulations have been published and accepted by the scientific community. Steven E. Katz, M.D. and Deborah M. Grzybowski, Ph.D. have been appointed to the Scientific Advisory Panel of the Intracranial Hypertension Research foundation (IHRF). Dr. Katz and former Fellow Dr. Marc Criden will be hosting the 2nd Annual IHRF conference for 200 patients in Houston, Texas in June of 2008.

Our division has ongoing basic science studies looking at arachnoid cells grown in cell culture and ex-vivo arachnoid membrane. We also have ongoing anatomical studies to evaluate the location and density of arachnoid granulations on the human brain. We are looking for a number of important receptors at the sites of cerebrospinal fluid production and egress to better understand how we might intervene to reduce intracranial pressure medically.

We are involved in a major clinical study looking at serum and cerebrospinal fluid in patients with IIH compared to age and weight matched controls. The goal of this study is to elucidate a number of factors that may be involved in the pathogenesis of the disease.
Ophthalmic Pathology
Elson L. Craig, M.D.

During the period July 1, 2006 to June 30, 2007, 679 tissues were received, examined, reported, and entered into the Pathology Archives of Ophthalmology. This total includes the following:

- 19 Enucleations, including 6 malignant melanomas
- 7 Eviscerations
- 43 Orbital tissues, including 14 lacrimal gland biopsies
- 63 Temporal artery biopsies
- 149 Eyelid lesions
- 62 Conjunctival tissues
- 172 Corneal tissues
- 6 Lenses extracted
- 20 Intraocular lenses removed
- 2 Intraocular lenses removed, including 1 iris melanoma and 1 iris cyst
- 15 Miscellaneous tissues, including 2 foreign bodies and 1 removed Baervelt implant
- 107 Gross only - Tissues that did not require a pathologic diagnosis, were submitted and entered into the archives
- 20 Outside cases submitted for further consultation

Oculoplastics
John Burns, M.D.

The Oculoplastic Surgery Service is committed to excellence in clinical care, research and teaching. Active participation in medical school teaching occurs in core curriculum instruction, physical diagnosis instruction, clinical rotations, elective rotations, and research projects. Resident teaching is organized with didactic lectures, weekly staffing of an Oculoplastics Clinic at the OSU campus, first year resident rotations in Oculoplastic Surgery, weekly surgery and clinic for Ophthalmic Plastic Surgery during the second year pediatric rotation, and third year resident Oculoplastic Surgery rotations. The American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Fellowship program compliment the residency teaching program, and provide additional educational and research resources to the residents. Members of the Oculoplastic service are Kenneth Cahill, M.D., Kelly Everman, M.D., Jill Foster, M.D., Steven Katz, M.D., Marsha Kavanagh, M.D., and James Moses, M.D. Local and national instructional courses are presented in oculo-facial surgery, pediatric oculoplastics, cosmetic facial surgery, blepharospasm, thyroid eye disease and ptosis. Research presentations and publications during this past year included topics of ptosis, the lacrimal outflow system, minimally invasive surgery, the use of tissue glue in place of sutures and cosmetic facial surgery.
Establishing a tradition in Ophthalmology

Pediatrics
Gary L. Rogers, M.D.

Outpatient clinic visits increased again this year to 8196 patient visits. The clinic continues to be staffed by two residents from The Ohio State University and an optometrist 3 ½ days a week. Surgically, the Department of Ophthalmology also continues to be extremely active. In the year 2006-2007, 2692 outpatient surgeries and 314 main OR cases were performed at Nationwide Children’s Hospital. Ophthalmology performed the greatest number of cases in the Children’s Surgery Center. The department participates in both funded and unfunded research. The Early Treatment for Retinopathy of Prematurity (ETROP) investigators are beginning to see randomized patients for the 6-year follow-up visits. Testers are coming out from the University of Arizona to perform acuity and visual field testing that will complete Phase II of the ETROP trial.

Several amblyopia protocols and a follow-up nasolacrimal duct study are being conducted in association with the Pediatric Eye Disease Investigator Group (PEDIG). Huan Sheng, Ph.D., recently completed two studies involving the corneal endothelium. Larry Leguire, Ph.D., continues to work with the OSU Department of Ophthalmology in functional MRI research. It is our goal to be a leader in the research of fMRI and changes to the visual cortex in patients with amblyopia and nystagmus.

Our department has added a fellowship trained pediatric Ophthalmologist, David L. Rogers, M.D. Dr. Rogers is actively involved in several new projects and has residents involved in his studies also. Other members of the department include Don Bremer, M.D, Mary Lou McGregor, M.D., Richard Golden, M.D., Cybil Bean-Cassady, M.D. Future plans include working with the hospital to increase the amount of space for both the laboratory and the clinic.

Refractive Surgery
David Castellano, M.D.

The Havener Eye Institute Refractive Surgery Division located at our Dublin location provides expert care designed to free patients from glasses or contact lenses. Treatments for myopia, hyperopia and astigmatism are available as well as monovision/blended vision treatments for patients over 40 with presbyopia.

We utilize the most advanced technology including the LADARVISION System which incorporates a radar eye tracker that scans and follows eye movement at 4,000 times per second. Custom Cornea or wavefront technology is also used to address the quality of visual outcomes, especially in low-light conditions.

During 2006, we integrated the newest version of the IntraLase femtosecond (FS) laser for use in LASIK procedures. The computer-guided ultra-fast IntraLase FS laser creates the corneal flap eliminating flap complications related to the hand-held microkeratome blade historically used to create corneal flaps. In the second step of LASIK, wavefront-guided technology maps the eye and then custom-corrects vision based upon the unique characteristics of the patient’s eye.

This all laser technology utilizing both wavefront-guided and femtosecond lasers has been approved for both U.S. military personnel and U.S. astronauts. More than 11 million LASIK procedures have been performed to date, making it the most common elective surgical procedure in the U.S.
Research
Cynthia Roberts, Ph.D.

For academic year 2007, the Department of Ophthalmology received thirty-seven new research awards and continued work on sixteen multiple year grants. These awards focus on: age related macular degeneration, diabetic macular edema, retinal vein occlusion, glaucoma, idiopathic intracranial hypertension, bacterial conjunctivitis, fungal keratitis and managing ocular hypertension. Funding sources include National Institute of Health/National Eye Institute, the Columbus Foundation, and Ohio Lions Eye Research Foundation, as well as numerous industry sponsorships. These research findings produced twenty-five peer reviewed publications and were reported in approximately fifty presentations at a variety of Ophthalmology related conferences around the world. We are dedicated to advancing medicine through research and making the world brighter for those suffering with eye diseases.

Retina
Alan D. Letson, M.D.

Dr. Alan Letson became the director of the Retina Division in March 2007. Our faculty consists of Frederick Davidorf, M.D., Carol Laxson, M.D., Alan Letson, M.D. and fellow, Ryan Deasy, M.D. Dr. John Christoforidis joined our division as an Assistant Professor in October 2006. Prior to joining us, Dr. Christoforidis was on staff at the Beth Israel Deaconess Hospital at Harvard Medical School. Dr. Christoforidis has had numerous publications and his research interest lies primarily with retinal vascular occlusions and imaging. Our retina physicians provide state-of-the-art treatment for all retinal disorders and perform complex surgeries for retinal detachment repair, diabetic retinopathy, and other debilitating diseases. Scott Savage continues to lead the Imaging Center which upgraded to high resolution digital color and fluorescein angiographic capabilities at both of our locations. High resolution ultrasound was purchased for our Ohio State location.

Our Retina Division is a tertiary care service which is responsible for the three missions of the College of Medicine; teaching, research, and clinical care. The retina rotation is a popular resident rotation where they are exposed to a wealth of medical and surgical retina. We have an active teaching schedule which includes training fellows, residents and medical students.

Research within our division involves both clinical trials and basic science genetic studies. Our physicians are involved in 17 randomized clinical trials. Studies sponsored by the National Eye Institute (NEI) are Complications of Age-Related Macular Degeneration (AMD) Prevention Trials (CAPT) and Randomized Trial of Lutein, Zeaxanthin and w-3 Fatty Acids in AMD (AREDS2) to evaluate potential treatment for AMD. Diabetic Retinopathy Clinical Research Network (DRCR) is also sponsored by the NEI and involves 6 trials evaluating potential treatments for diabetic retinopathy. Lastly, we are participating in the Actions to Control Cardiovascular Risk Factors in Diabetes Eye Study (ACCORD) in collaboration with the Department of Endocrinology.

Industry sponsored studies involving treatment modalities for age-related macular degeneration includes Genentech Sailor, Genentech Horizon, Genentech Pier, Eyetech Level, and Novartis Veritas. We are also participating in the Allergan Posurdex trial which evaluates vein occlusions.
Melanoma Research

Molecular Genetics of Uveal Melanomas

The ophthalmic oncology division, under the leadership of Professor Frederick Davidorf, M.D., has studied the prognosis of malignant melanoma of the choroid for the past 30 years. This is the most common primary intra-ocular tumor found in adults. Our division has identified potential novel therapies and prognostic factors that could influence the course of this cancer. Molecular genetic studies reveal striking genetic differences in tumor subtypes; even those with similar histopathological characteristics. This may explain why one patient with malignant melanoma is treated and cured while another patient dies of metastatic disease.

Through the philanthropy of Patti and Warner Blow, we have developed multidisciplinary tumor service. This includes clinical ophthalmology, human cancer genetics, medical oncology and basic molecular genetic research. Patients referred to the oncology division with choroidal melanomas have routine ophthalmological evaluation by the retina faculty. Systemic evaluations are conducted by Dr. Tom Olencki and Dr. Kari Kendra, medical oncologists specializing in malignant melanomas. Included in the pre-treatment evaluation, all ocular melanoma patients have imaging studies performed using high resolution (3T, 7T) MRI technology available at OSU under the direction of Dr. Michael Knopp. Genetic personnel, Rob Pilarski and Jennifer LaJeunesse, obtain complete genetic patient histories and blood samples for molecular genetic analysis.

Mohamed Abdel-Rahman, M.D., Ph.D., a pathologist and geneticist, directs the molecular genetic research for the uveal melanoma study, assisted by Getachew Boru, Ph.D. and Andrew Kin, B.S. Notable milestones achieved by our research staff include the finding of several molecular genetic markers that can identify aggressive uveal melanomas. These markers can be utilized for early diagnosis of these tumors. Also, these markers can hopefully be used as potential targets for therapy. Our division is currently focusing on the study of several of these molecular targets that can explain the high incidence of liver metastasis in patients with uveal melanoma. Other notable achievements of our research staff include the identification of higher-frequency of some cancers (including colon cancer) in patients with uveal melanomas and their first-degree relatives. We are currently conducting further studies to evaluate the potential genetic alterations that could explain these findings.

We hope our MRI imaging studies will provide a non-invasive modality to distinguish malignant from non-malignant lesions and help monitor therapy. It is the belief of our dedicated research team that this multidisciplinary approach to the management of patients with malignant melanoma of the uvea will ultimately lead to target therapy in patients identified as high-risk. The destruction of micro metastasis may lead to melanoma cures, previously not possible.

Glaucoma Research

Memantine

The glaucoma division has just completed its four-year participation in a clinical trial sponsored by Allergan to evaluate the safety and effectiveness of oral Memantine. Memantine is considered in a class of drugs referred to as neuroprotectors.

Memantine has been used in Europe for 20 years for central nervous system (CNS) indications such as for the treatment of dementia syndrome, spastic disorders, and Parkinson’s syndrome. In 2003, the FDA approved the use of Memantine (Namenda®) for the treatment of Alzheimer’s. Allergan, in its ongoing pursuit of developing drugs for the treatment of eye disease, began researching Memantine for the treatment of glaucoma.

Glaucoma is a disease characterized by damage to the cells around the optic nerve that will result, if left untreated, in eventual blindness. The prevailing theory is that this damage is caused by increased pressure (IOP) inside the eye. However, there is research to suggest that increased IOP is only part of the picture of understanding the cause of glaucoma. Blindness from glaucoma may also result from the build up of a toxin within the eye.

A neurotransmitter called glutamate stimulates the nerve cells used during vision. It has been found that too much glutamate in the eye can act as a toxin, actually causing death to the cells surrounding the optic nerve. Memantine has been shown to decrease the excess production of glutamate. It is theorized that Memantine used in the treatment of glaucoma could help prevent the progression of this blinding disease.

In 1999, Allergan began recruitment for the Memantine clinical trial, enrolling 1136 patients and involving clinics in the U.S., Canada, Brazil, Europe, Australia, and New Zealand. As of September 2006, all patients concluded their participation in this study. Now, the final process of data analysis will begin with results to be published in two years. Hopefully, findings will be favorable and Memantine can be added to the arsenal of medications that fight the progression of glaucoma.
Neuro-Ophthalmology Research

Under Pressure: Research in CSF Outflow Homeostasis

Idiopathic intracranial hypertension (IIH) is a clinical condition of increased intracranial pressure (ICP) that causes severe headaches, tinnitus, blurred vision, and transient visual obscurations. If left untreated, chronic increased ICP can compress the optic nerve head, permanently damaging it, resulting in blindness. In IIH disturbed cerebrospinal fluid (CSF) dynamics may result from an increased resistance to CSF outflow at the arachnoid granulations (AGs) (figure A, yellow arrow indicates direction of CSF flow). Deborah Grzybowski, Ph.D. and Dr. Steven Katz, with graduate students David Holman and Shelley Glimcher, have modeled the outflow of CSF through human AGs using cell culture (in-vitro) and whole tissue (ex-vivo) perfusion models.

This work will provide knowledge of the mechanism of fluid and protein transport through the human arachnoid membrane, create novel ways to increase CSF outflow, modulate clearance of undesired proteins, and provide early disease intervention. In addition to implications for IIH, outflow through the arachnoid membrane has been implicated in a number of other disorders including hydrocephalus, and Alzheimer’s disease.

In these models, human AG tissue is collected and the AG cells are isolated and grown on filter inserts or the tissue is fit under an o-ring and placed into an Ussing chamber (figure B). Cells and/or tissue are perfused at physiologic pressure with fluorescent microparticles and fixed under experimental pressure. Fixed tissue is processed for transmission electron microscopy (TEM) or cryo-sectioned and stained for visualization. In-vitro and ex-vivo permeability results showed flow through the AG cells was uni-directional in the physiologic direction from the basal to apical (B→A) cell membrane. Microparticles were identified coursing up through the neck of arachnoid granulations, into and out of the arachnoid cap cell layer (figure C, red arrows mark microparticles). In figure D a microparticle is shown being released from the apical membrane.

TEM showed extra-cellular cisternal spaces between overlapping AG cells suggesting a pathway for para-cellular fluid transport. Several large intracellular vacuoles (which did not stain with ruthenium red, yellow arrow heads) within the cytoplasm are shown suggesting a trans-cellular pathway for fluid flow (figure E). Red arrow heads indicate cellular boundaries stained with ruthenium red.

Retina Research

ARED 2 Study

The Age-Related Eye Disease Study 2 (AREDS2) is a multi-center, randomized trial designed to assess the effects of oral supplementation of macular xanthophylls (lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA]) on the progression to advanced age-related macular degeneration (AMD). An additional goal of the study is to assess whether forms of the AREDS nutritional supplement with reduced zinc and/or no beta-carotene works as well as the original supplement in reducing the risk of progression to advanced AMD. Approximately 4,000 AREDS2 participants aged 50 to 85 years will participate who have either: 1) bilateral large drusen or 2) large drusen in one eye and advanced AMD (neovascular AMD or central geographic atrophy) in the fellow eye. All participants will be offered additional treatment with the study formulation used in AREDS. For those who elect to take this additional supplement, which is now considered the standard of care, further randomization may occur to evaluate the possibility of deleting the beta-carotene and decreasing the original levels of zinc in the formulation for the treatment of AMD.
Grants

JA Burns (PI), KV Cahill, JA Foster. Evaluation of botulinum A toxins antigenic characteristics, Merz Pharmaceuticals, 2006-08.

RB Chambers (PI), FH Davidorf, LJ Chorich. A phase IIIb, single masked, multicenter, randomized study to evaluate the safety and tolerability of ranibizumab in naive and previously treated subjects with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) (SAILOR). Genentech Pharmaceuticals, 2005-07.

RB Chambers (PI), LJ Chorich, FH Davidorf, AD Letson. Safety assessment of intravitreal Lucentis for AMD: a phase IIIB multicenter study to evaluate the safety and tolerability of ranibizumab (0.3 mg and 0.5 mg) in naive and previously treated subjects with CNV secondary to AMD (SAILOR II), Genentech Pharmaceuticals, 2006-07.

FH Davidorf (PI), RB Davidorf. Phase IIb randomized, double-masked, sham controlled, multi-center study comparing photodynamic therapy with Verteporfin (Visudyne) plus two different dose regimens of intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to AMD (VERITAS) Novartis Pharmaceuticals, 2005-08.


FH Davidorf (PI), LJ Chorich, RB Chambers. Phase IIIb, Multi-center, randomized, double masked, sham injection controlled study of the efficacy and safety of rhuFab V2 (ranibizumab) in subjects with subfoveal choroidal neovascularization (CNV) with or without classic CNV secondary to age-related macular degeneration (PIER), Genentech Pharmaceuticals, 2004-06.


FH Davidorf (PI), RB Chambers, R Deasy. An open-label, multi-center extension study to evaluate the safety and tolerability of ranibizumab in subjects with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) who have completed the treatment phase of a genentech-sponsored ranibizumab study (HORIZON), Genentech Pharmaceuticals, 2006-08.


L Leguire (PI). Ohio amblyope registry subcontract with the Ohio Optometric Association, Ohio Department of Health Save Our Sight Children’s Program, 2000-07.

RG Lembach (PI), TF Mauger, C Roberts. Evaluation of the utility of intra-operative topography to optimize corneal shape during penetrating keratoplasty, BIOMEC, 2004-07.

AD Letson (PI), JB Christoforidis, FH Davidorf, R Deasy. Phase III, double-masked, multicenter, randomized, sham-controlled study of the efficacy and safety of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RIDE), Genentech Pharmaceuticals, 2007-09.


AD Letson (PI), FH Davidorf, RB Chambers, LJ Chorich. A Phase IV, open label, multi-center, trial of maintenance intravitreous injections of Macugen® (pegaptanib sodium) given every 4 weeks for 48 weeks in subjects with subfoveal neovascular age-related macular degeneration (AMD) initially treated with a modality resulting in maculopathy improvement (LEVEL), OSI/Eyetech Pharmaceuticals, 2006-08.

TF Mauger (PI), RG Lembach, ME Dangel, R Harder-Smith. Rates and risk factors for fungal keratitis among contact lens wearers, John Hopkins University, 2006-08.

TF Mauger (PI), RG Lembach, ME Dangel M.D. A study to evaluate the clinical and microbial efficacy of 0.6% ISV-403 compared to vehicle in the treatment of bacterial conjunctivitis, Bausch and Lomb, 2006-07.

TF Mauger (PI), RG Lembach, D Castellano, R Harder-Smith. A double-masked randomized study of the safety and effectiveness of DYMIE as an agent for selective staining of the anterior capsule during cataract surgery, Auqmen Biopharmaceuticals, N.A., Inc. 2006-08.

FW Price (PI), TF Mauger. Clinical investigation of OPHTEC iris reconstruction lens model 311, OPHTEC USA, Inc., June 2007


R Xu (PI), CJ Roberts, L Leguire. Functional image of visual cortex and retina tissue for vision pathophysiology, Children’s Hospital Collaborative Research Award, 2006-08.


Publications & Presentations

Publications

A PRESENTATIONS


Establishing a tradition in Ophthalmology


Weber PA. “Personalizing Your Interaction with Your Patient.” In: The Clinical Teaching Handbook Edited by Hudson A and Watson DC. Columbus, OH: The Ohio State College of Medicine, 2007.
Presentations

Abdel-Rahman MH, Boru G, Davidorf FH
“High frequency of cMET over-expression in uveal melanoma through altered gene regulation rather than mutation and amplification of the cMET gene”
ARVO Annual Meeting
Fort Lauderdale, Florida
May 2007

Cahill, KV
“Pediatric Nasolacrimal Disorders”
AAO Annual Meeting
Las Vegas, Nevada
November 12, 2006

Cahill, KV
“Orbital Fractures”
Cleveland Ophthalmological Society
Grand Rounds
Cleveland, Ohio
February 13, 2007

Cahill, KV
“Botox: Needs and Desires”
Cleveland Ophthalmological Society
Cleveland, Ohio
February 13, 2007

Cahill, KV
“Grafts”
2007 OPSCO Continuing Education
Columbus, Ohio
March 13, 2007

Cahill, KV
“Thyroid Eye Disease”
Central Ohio Graves Disease Support Group
Columbus, Ohio
October 14, 2007

Davidorf FH, Boru G, Abdel-Rahman MH, Eng C
“Malignant Melanoma of the Uvea: A new paradigm”
Yonsei Retina Symposium
Seoul, South Korea
September 2006

Davidorf FH, Abdel-Rahman MH, Craven MA, Ohr M, Jarjoura D
“Higher frequency of colon cancer in uveal melanoma patients and their relatives compared to the general population”
ARVO Annual Meeting
Fort Lauderdale, Florida
May 2007

Grzybowski DM
“Mechanism of CSF Outflow Through Human Arachnoid Granulations using in-vitro and ex-vivo Perfusion Models”
North American Neuro-Ophthalmology Society Annual Meeting
Snowbird, Utah
February 13, 2007

Grzybowski DM
“CSF Outflow: The Arachnoid Membrane”
Department of Neurosurgery Grand Rounds, Brown University
Providence, Rhode Island
January 8, 2007

Grzybowski DM
“CSF Outflow: The Arachnoid Membrane, Clearing the Drain”
The Brain Child Hydrocephalus Meeting
Brown University
Providence, Rhode Island
November 14, 2006

Grzybowski DM
IH Research, Part I: Overview of Current Research and Areas of Future Study Intracranial Hypertension Research Foundation Annual Meeting
Casey Eye Institute, OHSU
Portland, Oregon
October 14, 2006

Grzybowski DM
“IH Research, Part II: Current Research at Ohio State University”
Intracranial Hypertension Research Foundation Annual Meeting
Casey Eye Institute, OHSU
Portland, Oregon
October 14, 2006

Katz SE
“Update on Pseudotumor Cerebri”
The OSU College of Medicine Alumni Reunion
Columbus, Ohio
September 1, 2006

Katz SE
“Pseudotumor Cerebri: Medical Management and Beyond”
Intracranial Hypertension Research Foundation Patient Conference
Casey Eye Institute
Oregon Health & Science University
Portland, Oregon
October 13, 2006

Katz SE
“On the Appropriate Physician to Manage Idiopathic Intracranial Hypertension”
Department of Neurology, OSU
Columbus, Ohio
April 27, 2007

Kashou N, Leguire LE, Roberts C, Rogers GL
“Functional Magnetic Resonance Imaging (fMRI) on Saccade and Pursuit at 3T”
ARVO Annual Meeting
Fort Lauderdale, Florida
May 2007

Lembach RG
“Contact Lens Fitting Post LASIK Ectasia”
American Academy of Ophthalmology Annual Meeting
Las Vegas, Nevada
November 11-13, 2006
Letson AD
“Angiography of Susac’s Syndrome”
3rd Annual Susac’s Symposium,
Columbus, Ohio
April 26, 2007

Letson AD
“Diabetic Retinopathy: Past, Present and
Future”
43rd Annual Diabetes Symposium
The Ohio State University
Columbus, Ohio
October 13, 2006

Roberts CJ
“Corneal Topography and IOL Power
Calculation”
XXIV Congress of the ESCRS
London, England
Sept. 9, 2006

Roberts CJ
“Biomechanics of the Cornea”
XXIV Congress of the ESCRS
London, England
Sept. 9, 2006

Roberts CJ
“Practical Interpretation of Elevation and
Curvature Maps”
XXIV Congress of the ESCRS
London, England
September 10, 2006

Roberts CJ
“Biomechanics of Corneal Response to
Ablation”
XXIV Congress of the ESCRS
London, England
September 11, 2006

Roberts CJ
“CLMI: A New Keratoconus Index”
Milan, Italy
September 14, 2006.

Roberts CJ
“Rasterstereography Corneal Topography:
What was Old is New Again!” Refr@ctive.
on-line Course, Pre-Operative Evaluation
and Diagnostics Session
Milan, Italy
September 15, 2006

Roberts CJ
“Curvature Gradient: the Advantages of a
Higher Order Topographic Shape Analy-
sis.” Refr@ctive.on-line Course, Pre-Op-
erative Evaluation and Diagnostics Session
Milan, Italy
September 15, 2006

Roberts CJ
“Quality of Vision Evaluation”
ESCRS Winter Refractive Surgery Meeting
Athens, Greece
February 2, 2007

Roberts CJ
“Biomechanics of the Cornea”
11th ESCR S Winter Refractive Surgery
Meeting
Athens, Greece
February 2, 2007

Roberts CJ
“Integration of Corneal Biomechanics into
the Treatments of Irregular Astigmatism”
Am. Soc. for Cataract & Refractive Surgery
San Diego, California
April 28, 2007

Roberts CJ
“Principles of Orbscan Topography and
Practical Interpretation of Elevation and
Curvature Maps”
Am. Soc. for Cataract & Refractive Surgery
San Diego, California
April 29, 2007

Roberts CJ
“Topographies of Biomechanical Changes”
Am. Soc. for Cataract & Refractive Surgery
San Diego, California
April 30, 2007

Roberts CJ
“Importance of Corneal Biomechanics in
Ophthalmology”
The Brazilian Society of Refractive Sur-
gery (BRSCRS)
Belo Horizonte, Brazil
June 2, 2006

Roberts CJ
“Corneal Biomechanics in Refractive
Surgery”
9th Swiss Refractive Congress
Lucerne, Switzerland
June 10, 2006.

Roberts CJ
“Wavefront Analysis versus Corneal To-
pography”
9th Swiss Refractive Congress
Lucerne, Switzerland
June 10, 2006

Roberts CJ
“Corneal Biomechanics and Intra-ocular
Pressure”
Italian Glaucoma Society
Sienna, Italy
June 16, 2006

Roberts CJ
“Corneal Biomechanics in Refractive
Surgery”
British Society for Refractive Surgery
Oxford, England
July 2, 2006

Roberts CJ
“Wavefront Analysis versus Corneal To-
pography”
British Society for Refractive Surgery
Oxford, England
July 2, 2006
Presentations
(Continued)

Roberts CJ
“The Cornea is not a Piece of Plastic”
New York Intra-Ocular Lens Implant Society (NYIOLIS)
New York, New York
November 2, 2006

Roberts CJ
“Corneal Biomechanics in Refractive Surgery and Glaucoma”
Grand Rounds, New York Eye and Ear Infirmary
New York, New York
November 3, 2006

Roberts CJ
“Biomechanical Considerations in Deciding between Surface Ablation or LASIK”
American Academy of Ophthalmology
Las Vegas, Nevada
November 11, 2006

Roberts CJ
“Biomechanics of the Cornea”
Kersley Lecture, Medical Contact Lens and Ocular Surface Association (MCLOSA)
London, England
November 17, 2006

Roberts CJ
“Hysteresis and Biomechanics”
Optometric Council on Refractive Technologies, American Academy of Optometry
Denver, Colorado
December 6, 2006

Roberts CJ
“Biomechanics of the Injured Cornea”
ARVO/AAO Joint Symposium
Denver, Colorado
December 8, 2006

Roberts CJ
“Predictability of Refractive Surgical Procedures”
Main Symposium on Fine-Tuning of Refractive Outcomes, Winter ESCRS
Athens, Greece
February 4, 2007

Roberts CJ
“Corneal Biomechanics in Glaucoma”
Rothschild Foundation, Bichat-Claude Bernard Hospital
Paris, France
March 19, 2007

Roberts CJ
“Laser-Tissue Interactions in Laser Trabeculoplasty”
Diplôme Inter Universitaire LASER & Médecine, Université Bordeaux 1 - Sciences et Technologies, Université Victor SEGALEN, Sciences médicales
Bordeaux, France
March 22, 2007

Roberts CJ
“Biomécanique cornéenne: rencontre avec une experte”
Bordeaux University, Ophthalmologic Department
Bordeaux, France
March 22, 2007

Roberts CJ
“Biomechanics of the Cornea following Surface Ablation, SBK, and LASIK,”
Sixth International Congress on Advanced Surface Ablation & SBK
 Ft. Lauderdale, Florida
May 5, 2007

Awards

The Best Doctors in America, 2007
John A. Burns, M.D.
Kenneth V. Cahill, M.D.
Matthew E. Dangel M.D.
Frederick H. Davidorf M.D.
Steven E. Katz M.D.
L. Carol Laxson M.D.
Richard G. Lembach M.D.
Alan D. Letson M.D.
Thomas F. Mauger M.D.
Paul A. Weber M.D.

Senior Achievement Award, 2007
American Academy of Ophthalmology
Richard G. Lembach, M.D.

Makley-Battles Resident Teaching Award, 2007
OSU Department of Ophthalmology
Alan D. Letson, M.D.
Robert Chambers, D.O.

America’s Top Ophthalmologists, 2006
Consumer’s Research Council of America
Alan D. Letson, M.D.

Landacre Honor Society Faculty Award, 2006
OSU Landacre Society
Paul A. Weber, M.D.

Champion of Family Medicine Award, 2007
OSU Department of Family Medicine
Paul A. Weber, M.D.

Leonard Tow Humanism in Medicine Award, 2006
Arnold P. Gold Foundation
Paul A. Weber, M.D.

Housestaff Humanism Award, 2007
The Ohio State Medical Center
Andrea Knellinger, M.D.
The Havener Eye Institute Alumni Reception was held in Las Vegas at Caesars Palace in the Pompeian Ballroom. Over 90 Alumni attended the event. This annual reception once again provided a wonderful way to reconnect with former colleagues and friends.

BUCKEYE FALL FORUM
BUCKEYES DEFEAT HAWKEYES

Ohio Stadium,
Columbus, OH

September 30, 2006

The Havener Eye Institute welcomed Edward N. Burney, MD and Jeffrey D. Horn, MD. as our guest lecturers for our 2nd Annual BuckEYE Fall Forum held in the Huntington Club at Ohio Stadium. Dr. Burney is from Case Western Reserve University and is Director of the Glaucoma Service. Dr. Horn is Assistant Professor of Corneal and Refractive Surgery at Vanderbilt University Medical Center in Nashville, Tennessee and specializes in cataract and LASIK surgery. The football game followed the CME session and the Ohio State Buckeyes beat the Iowa Hawkeyes 38-17. Physicians, staff, and friends attended this family fun evening held in the Presidential suite at The Ohio State University Stadium.
SECOND ANNUAL BUCKEYE GOLF CLASSIC
HONORARY GUEST: THAD MATTA

Golf Club of Dublin
Columbus, OH

May 21, 2007

The Havener Eye Institute hosted it’s 2nd Annual Golf Classic on May 21, 2007 presented by Fifth Third Bank. Thad Matta, The Ohio State men’s basketball coach, came out to support the Havener Eye Institute and meet players. There wasn’t a cloud in the sky as the 93 golfers teed off at the Golf Club of Dublin. The outing was won by Lee Rudibaugh, Alan Wallingsford, Scott Bellinger, and Mark McConnell with a score of 59. The second place winners were Paul Weber, Alan Letson, Doug Wyatt, and Mark Sbrochi. The third place winners were Jamie Menges, Chad Stuckey, Carrie Lembach, and Christy Float. Through sponsorships, raffle prizes, and Thad Matta autographed basketballs this event raised $36,000 allowing us to donate more than $25,000 to resident education and research projects.
The 50th Annual Postgraduate Symposium was held in the Hilton Columbus at Easton. This year’s topic was Comprehensive Clinical Conundrums. Issues addressed included current diagnosis and treatment of strabismus, the differential diagnosis of Grave’s ophthalmology, and the role of steroids in the treatment of bacterial keratitis. Speakers included Gary Abrams, M.D., James Garrity, M.D., David L. Guyton, M.D., Jay Katz, M.D., Grace Levy-Clarke, M.D., Francis S. Mah, M.D., Quan Dong Nguyen, M.D., Francis Price, M.D., Jonathan Trobe, M.D., and Robert L. Hamlin, D.V.M., Ph.D. This year’s course director was Thomas Mauger, M.D.

The 1st Annual Havener Society reception and dinner was held at the Hilton Easton in the Grand Ballroom on March 2, 2007. Havener Society members were honored with a gift following dinner for their generosity and support. A huge “Thank You” to those inaugural members for their devotion to the Havener Eye Institute over the years.
Our faculty, residents, and alumni are committed to restoring vision through eye surgery missions around the world.

Establishing a tradition in Ophthalmology

International Outreach Missions